<DOC>
	<DOCNO>NCT00803049</DOCNO>
	<brief_summary>The primary objective study document long-term safety tolerability teriflunomide Multiple Sclerosis ( MS ) participant relapse . The secondary objective document long-term efficacy disability progression , relapse rate Magnetic Resonance Imaging ( MRI ) parameter .</brief_summary>
	<brief_title>Long Term Safety Efficacy Study Teriflunomide 7 mg 14 mg Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>Participants complete EFC6049 ( HMR1726D/3001 ) study give opportunity continue extension study ; - participant receive teriflunomide 7 mg 14 mg blindly maintain dose teriflunomide . - participant receive placebo randomize 1:1 ratio teriflunomide 7 mg 14 mg . The study period per participant break follow : - Double-blind treatment : maximum 288 week teriflunomide commercially available country participant live , - Post-washout follow-up : 4 week last treatment intake . No post-washout follow participant continue teriflunomide treatment obtain commercial form end study . The total duration extension 292 week ( 6 year ) first participant enrol teriflunomide commercially available country participant live .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<criteria>Participant complete previous doubleblind placebocontrolled study EFC6049 meet criterion treatment withdrawal . Willingness participate longterm safety/efficacy trial . Any known condition circumstance would prevent investigator 's opinion , compliance completion study . The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Oral treatment</keyword>
</DOC>